MXCT Stock Forecast: MaxCyte, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for MaxCyte, Inc. is $4.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth.
One number for the whole business
Consensus tells you what everyone already believes. The model scores MaxCyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Quality (47): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MXCT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MXCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | Craig-Hallum | Maintains | Buy | $7.00 → $5.00 |
| 11 Aug 2025 | BTIG | Downgrade | Neutral | — |
| 7 Aug 2025 | William Blair | Downgrade | Market Perform | — |
| 22 July 2025 | Stephens & Co. | Assumes | Overweight | $6.00 |
| 12 Mar 2025 | Stifel | Maintains | Buy | — |
| 23 Apr 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 13 Mar 2024 | BTIG | Maintains | Buy | — |
| 13 Mar 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 29 Nov 2023 | Craig-Hallum | Initiates | Buy | — |
| 5 Oct 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 28 Mar 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 15 Aug 2022 | BTIG | Maintains | Buy | — |
| 24 Aug 2021 | BTIG | Initiates | Buy | — |
| 24 Aug 2021 | Cowen & Co. | Initiates | Outperform | — |
| 24 Aug 2021 | Stephens & Co. | Initiates | Overweight | — |
| 24 Aug 2021 | Stifel | Initiates | Buy | — |
| 24 Aug 2021 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MXCT.
This page is one stock. Monday covers all of them.
MXCT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MXCT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, MaxCyte, Inc. returned −16.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MXCT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 4.1×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 26% of US stocks
Cheaper than 73% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 77.0%
- Operating margin
- −85.5%
- Net margin
- —
Higher than 89% of US stocks
Higher than 15% of US stocks
- Return on equity
- −16.9%
- Return on assets
- −9.3%
- Dividend yield
- —
Higher than 33% of US stocks
Higher than 27% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MaxCyte, Inc. has a market value of $141.5M and an enterprise value of $57.1M.
Revenue in the twelve months to 30 June 2026: $31.1M. The latest quarter shrank 14.5% year on year.
Net income over the same four quarters: −$35.6M, a −114.8% net margin.
Diluted earnings per share, trailing twelve months: −$0.33.
Free cash flow in the twelve months to 30 June 2026: −$23.8M.
MaxCyte, Inc. employs 91 people — $341K of revenue per employee.
Data provided by Twelve Data
MXCT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MXCT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own MaxCyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MXCT
What is the MXCT stock price forecast for 2026-2027?
The median 12-month analyst price target for MaxCyte, Inc. is $4.5, with estimates ranging from $2.43 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MXCT stock a buy right now?
Of the 6 analysts covering MaxCyte, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MaxCyte, Inc. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MXCT?
As at 21 Nov 2026, MaxCyte, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
Will MXCT stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $4.5, and Ticker Nerd's factor model ranks MaxCyte, Inc. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MXCT stock forecast for 2030?
No analyst covering MaxCyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MXCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.43 to $5 over the next 12 months.
How has MXCT stock performed over the past year?
MaxCyte, Inc. returned -16.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MaxCyte, Inc. do?
MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development. MaxCyte designs and commercializes non-viral flow electroporation systems, proprietary processing assemblies, and consumables that help biotechnology and pharmaceutical companies introduce biological cargo into cells with precision and consistency.
About MaxCyte, Inc.
MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development. MaxCyte designs and commercializes non-viral flow electroporation systems, proprietary processing assemblies, and consumables that help biotechnology and pharmaceutical companies introduce biological cargo into cells with precision and consistency. Its platform is used across drug discovery, translational research, and biomanufacturing, supporting applications in gene editing, immuno-oncology, and other advanced cell-based medicines. The company also offers licensing arrangements tied to partner programs, making its technology part of broader therapeutic development workflows. Headquartered in Rockville, Maryland, MaxCyte serves a global customer base involved in next-generation cell therapeutics and related research.
CEO Mr. Maher Masoud · 91 employees · United States · https://www.maxcyte.com